Background: Iron supplementation is generally recommended for blood donors even though there are inter-individual differences in iron homeostasis. Methods: Ferritin levels of repeat donors were compared with first-time donors, retrospectively. Prospectively, we tested 27 male repeat donors for the following parameters at the day of blood donation as well as 1, 3, 7, 10, and 56 days thereafter: ferritin, hepcidin, transferrin, transferrin receptor, hemoglobin, erythropoietin, reticulocytes, hemoglobin in reticulocyte, twisted gastrulation protein homolog 1, and growth differentiation factor-15. Results: 56 days after blood donation, donors' average ferritin dropped to 55% (range 30-100%) compared to the initial value. Of all tested parameters hepcidin showed the highest and most significant changes beginning 1 day after donation and lasting for the whole period of 56 days. Along with ferritin, there was a high variation in hepcidin levels indicating inter-individual differences in hepcidin response to iron loss. Donors with a hepcidin/ferritin quotient < 0.3 regained 60% of their initial ferritin after 56 days, while those with a quotient ≥ 0.3 reached less than 50%. Conclusion: As hepcidin appears to integrate erythropoietic and iron-loading signals, clinical measurement of hepcidin (together with the hepcidin-ferritin ratio) may become a useful indicator of erythropoiesis and iron kinetics.

Keywords:
Hematology, Health research methodology, Red cells, Donors
1.
Chen PP, Short TG, Leung DH, Oh TE: A clinical evaluation of the Hemocue haemoglobinometer using capillary, venous and arterial samples. Anaesth Intensive Care 1992;20:497-500.
2.
James V, Jones KF, Turner EM, Sokol RJ: Statistical analysis of inappropriate results from current Hb screening methods for blood donors. Transfusion 2003;43:400-404.
3.
Lotfi R, Wernet D, Starke U, Northoff H, Cassens U: A noninvasive strategy for screening prospective blood donors for anemia. Transfusion 2005;45:1585-1592.
4.
Rippmann CE, Nett PC, Popovic D, Seifert B, Pasch T, Spahn DR: Hemocue, an accurate bedside method of hemoglobin measurement? J Clin Monit 1997;13:373-377.
5.
Simon TL: Iron, iron everywhere but not enough to donate. Transfusion 2002;42:664.
6.
Baart AM, van Noord PA, Vergouwe Y, Moons KG, Swinkels DW, Wiegerinck ET, de Kort WL, Atsma F: High prevalence of subclinical iron deficiency in whole blood donors not deferred for low hemoglobin. Transfusion 2013;53:1670-1677.
7.
Garry PJ, Koehler KM, Simon TL: Iron stores and iron absorption: effects of repeated blood donations. Am J Clin Nutr 1995;62:611-620.
8.
Jelkmann W: Regulation of erythropoietin production. J Physiol 2011;589:1251-1258.
9.
Gardenghi S, Marongiu MF, Ramos P, Guy E, Breda L, Chadburn A, Liu Y, Amariglio N, Rechavi G, Rachmilewitz EA, Breuer W, Cabantchik ZI, Wrighting DM, Andrews NC, de SM, Giardina PJ, Grady RW, Rivella S: Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin. Blood 2007;109:5027-5035.
10.
Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, Kaplan J: Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004;306:2090-2093.
11.
Talbot NP, Lakhal S, Smith TG, Privat C, Nickol AH, Rivera-Ch M, Leon-Velarde F, Dorrington KL, Mole DR, Robbins PA: Regulation of hepcidin expression at high altitude. Blood 2012;119:857-860.
12.
Pasricha SR, McQuilten Z, Westerman M, Keller A, Nemeth E, Ganz T, Wood E: Serum hepcidin as a diagnostic test of iron deficiency in premenopausal female blood donors. Haematologica 2011;96:1099-1105.
13.
Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T: Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 2003;101:2461-2463.
14.
Kemna E, Pickkers P, Nemeth E, van der Hoeven H, Swinkels D: Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood 2005;106:1864-1866.
15.
Ganz T, Olbina G, Girelli D, Nemeth E, Westerman M: Immunoassay for human serum hepcidin. Blood 2008;112:4292-4297.
16.
Zaritsky J, Young B, Wang HJ, Westerman M, Olbina G, Nemeth E, Ganz T, Rivera S, Nissenson AR, Salusky IB: Hepcidin - a potential novel biomarker for iron status in chronic kidney disease. Clin J Am Soc Nephrol 2009;4:1051-1056.
17.
Ginzburg Y, Rivella S: Beta-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism. Blood 2011;118:4321-4330.
18.
Ashby DR, Gale DP, Busbridge M, Murphy KG, Duncan ND, Cairns TD, Taube DH, Bloom SR, Tam FW, Chapman R, Maxwell PH, Choi P: Erythropoietin administration in humans causes a marked and prolonged reduction in circulating hepcidin. Haematologica 2010;95:505-508.
19.
Pak M, Lopez MA, Gabayan V, Ganz T, Rivera S: Suppression of hepcidin during anemia requires erythropoietic activity. Blood 2006;108:3730-3735.
20.
Kautz L, Jung G, Valore EV, Rivella S, Nemeth E, Ganz T: Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat Genet 2014;46:678-684.
21.
Tanno T, Bhanu NV, Oneal PA, Goh SH, Staker P, Lee YT, Moroney JW, Reed CH, Luban NL, Wang RH, Eling TE, Childs R, Ganz T, Leitman SF, Fucharoen S, Miller JL: High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 2007;13:1096-1101.
22.
Tanno T, Noel P, Miller JL: Growth differentiation factor 15 in erythroid health and disease. Curr Opin Hematol 2010;17:184-190.
23.
Tanno T, Porayette P, Sripichai O, Noh SJ, Byrnes C, Bhupatiraju A, Lee YT, Goodnough JB, Harandi O, Ganz T, Paulson RF, Miller JL: Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. Blood 2009;114:181-186.
24.
Beguin Y: Soluble transferrin receptor for the evaluation of erythropoiesis and iron status. Clin Chim Acta 2003;329:9-22.
25.
Huebers HA, Beguin Y, Pootrakul P, Einspahr D, Finch CA: Intact transferrin receptors in human plasma and their relation to erythropoiesis. Blood 1990;75:102-107.
26.
Mast AE, Schlumpf KS, Wright DJ, Custer B, Spencer B, Murphy EL, Simon TL: Demographic correlates of low hemoglobin deferral among prospective whole blood donors. Transfusion 2010;50:1794-1802.
27.
Radtke H, Tegtmeier J, Rocker L, Salama A, Kiesewetter H: Daily doses of 20 mg of elemental iron compensate for iron loss in regular blood donors: a randomized, double-blind, placebo-controlled study. Transfusion 2004;44:1427-1432.
28.
Mast AE, Foster TM, Pinder HL, Beczkiewicz CA, Bellissimo DB, Murphy AT, Kovacevic S, Wroblewski VJ, Witcher DR: Behavioral, biochemical, and genetic analysis of iron metabolism in high-intensity blood donors. Transfusion 2008;48:2197-2204.
29.
Tarkun P, Mehtap O, Atesoglu EB, Geduk A, Musul MM, Hacihanefioglu A: Serum hepcidin and growth differentiation factor-15 (GDF-15) levels in polycythemia vera and essential thrombocythemia. Eur J Haematol 2013;91:228-235.
30.
Casanovas G, Spasic MV, Casu C, Rivella S, Strelau J, Unsicker K, Muckenthaler MU: The murine growth differentiation factor 15 is not essential for systemic iron homeostasis in phlebotomized mice. Haematologica 2013;98:444-447.
31.
Tanno T, Rabel A, Lee YT, Yau YY, Leitman SF, Miller JL: Expression of growth differentiation factor 15 is not elevated in individuals with iron deficiency secondary to volunteer blood donation. Transfusion 2010;50:1532-1535.
32.
Hoffbrand AV, Ganeshaguru K, Hooton JW, Tattersall MH: Effect of iron deficiency and desferrioxamine on DNA synthesis in human cells. Br J Haematol 1976;33:517-526.
33.
Furukawa T, Naitoh Y, Kohno H, Tokunaga R, Taketani S: Iron deprivation decreases ribonucleotide reductase activity and DNA synthesis. Life Sci 1992;50:2059-2065.
34.
Ward RJ, Crichton RR, Taylor DL, Della CL, Srai SK, Dexter DT: Iron and the immune system. J Neural Transm 2011;118:315-328.
35.
Finch CA, Miller LR, Inamdar AR, Person R, Seiler K, Mackler B: Iron deficiency in the rat. Physiological and biochemical studies of muscle dysfunction. J Clin Invest 1976;58:447-453.
36.
Ackrell BA, Maguire JJ, Dallman PR, Kearney EB: Effect of iron deficiency on succinate- and NADH-ubiquinone oxidoreductases in skeletal muscle mitochondria. J Biol Chem 1984;259:10053-10059.
37.
Hillgrove T, Moore V, Doherty K, Ryan P: The impact of temporary deferral due to low hemoglobin: future return, time to return, and frequency of subsequent donation. Transfusion 2011;51:539-547.
© 2015 S. Karger GmbH, Freiburg
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.